35 results
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
. Nature Reviews Disease Primers. 2021, 7(1), 6.
Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
11 Oct 23
Entry into a Material Definitive Agreement
8:13am
of cancer-related death.3
Nine out of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
28 Apr 23
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
8:30am
of ten cases of HCC are caused by chronic liver disease, which includes chronic hepatitis B and C infection, non-alcoholic fatty liver disease (NAFLD), non
8-K
EX-99.1
TPST
Tempest Therapeutics Inc
16 Jul 21
Other Events
4:31pm
of the EP2 and EP4 receptors at trough exposure, was associated with reduced GI tolerability that limited chronic dosing by subjects on the BID schedule … will improve gut homeostasis and tolerability for chronic dosing while maintaining the Cmax drug levels that Tempest believes block EP2/EP4 receptor
8-K
EX-99.1
9otgni3a
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am
8-K
EX-99.1
1stla3a
6 Apr 20
Cost Associated with Exit or Disposal Activities
7:16am
8-K
EX-99.1
qmv9ocf pl0ep8q235
10 Feb 20
Millendo Therapeutics Appoints Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer
8:42am
8-K
EX-99.1
tnhzm cdafi
13 Jan 20
Results of Operations and Financial Condition
6:03am
424B5
624yhx6bi 5vf
5 Dec 19
Prospectus supplement for primary offering
4:06pm
424B5
gqoaqhnlyi7vic
4 Dec 19
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
gnca gtv4hdi4
29 Mar 19
Millendo Reports Full Year 2018 Operating and Financial Results
7:20am
8-K
EX-99.1
q0913okm
22 Mar 19
Presentation to Lorem Ipsum Dolor May 2018 Corporate Presentation March 2019
5:14pm